Year |
Citation |
Score |
2011 |
Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry. 26: 1236-43. PMID 22068922 DOI: 10.1002/Gps.2669 |
0.47 |
|
2011 |
Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry. 26: 356-63. PMID 21312297 DOI: 10.1002/Gps.2534 |
0.468 |
|
2011 |
Grossberg GT, Olin JT, Somogyi M, Meng X. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. International Journal of Clinical Practice. 65: 465-71. PMID 21309961 DOI: 10.1111/J.1742-1241.2011.02641.X |
0.334 |
|
2011 |
Grossberg G, Meng X, Olin JT. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 26: 65-71. PMID 21282280 DOI: 10.1177/1533317510391240 |
0.473 |
|
2010 |
Sadowsky CH, Dengiz A, Meng X, Olin JT. Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results. Primary Care Companion to the Journal of Clinical Psychiatry. 12. PMID 21274364 DOI: 10.4088/Pcc.09M00852Oli |
0.412 |
|
2010 |
Grossberg GT, Schmitt FA, Xiangyi Meng, Tekin S, Olin J. Effects of transdermal rivastigmine on ADAS-Cog items in mild-to-moderate Alzheimer's disease American Journal of Alzheimer's Disease and Other Dementias. 25: 627-633. PMID 21131668 DOI: 10.1177/1533317510385808 |
0.454 |
|
2010 |
Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. Cns Neuroscience & Therapeutics. 16: 330-6. PMID 20950329 DOI: 10.1111/J.1755-5949.2010.00182.X |
0.496 |
|
2010 |
Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Current Medical Research and Opinion. 26: 2441-7. PMID 20828359 DOI: 10.1185/03007995.2010.513849 |
0.413 |
|
2010 |
Olin JT, Aarsland D, Meng X. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dementia and Geriatric Cognitive Disorders. 29: 510-5. PMID 20523050 DOI: 10.1159/000305100 |
0.425 |
|
2010 |
Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders. 29: 406-12. PMID 20502014 DOI: 10.1159/000296073 |
0.497 |
|
2010 |
Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 25: 347-52. PMID 20392862 DOI: 10.1177/1533317510365344 |
0.433 |
|
2010 |
Schmitt FA, Aarsland D, Brønnick KS, Meng X, Tekin S, Olin JT. Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. American Journal of Alzheimer's Disease and Other Dementias. 25: 407-13. PMID 20392860 DOI: 10.1177/1533317510367486 |
0.452 |
|
2010 |
Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. International Journal of Clinical Practice. 64: 651-60. PMID 20102418 DOI: 10.1111/J.1742-1241.2009.02330.X |
0.408 |
|
2010 |
Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. International Journal of Clinical Practice. 64: 188-93. PMID 20089009 DOI: 10.1111/J.1742-1241.2009.02253.X |
0.424 |
|
2010 |
Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clinical Drug Investigation. 30: 41-9. PMID 19995097 DOI: 10.2165/11531270-000000000-00000 |
0.455 |
|
2010 |
Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Current Medical Research and Opinion. 26: 263-9. PMID 19929593 DOI: 10.1185/03007990903434914 |
0.503 |
|
2010 |
Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). International Journal of Geriatric Psychiatry. 25: 419-26. PMID 19670390 DOI: 10.1002/Gps.2355 |
0.49 |
|
2010 |
Safirstein B, Meng X, Olin JT. Rivastigmine and concomitant memantine in alzheimer's disease: Safety and tolerability Cns Spectrums. 15: 594-598. |
0.312 |
|
2009 |
Sadowsky CH, Dengiz A, Olin JT, Koumaras B, Meng X, Brannan S. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 24: 267-75. PMID 19293130 DOI: 10.1177/1533317509333037 |
0.432 |
|
2008 |
Williams JBW, Kobak KA, Bech P, Engelhardt N, Evans K, Lipsitz J, Olin J, Pearson J, Kalali A. The GRID-HAMD: Standardization of the Hamilton depression rating scale International Clinical Psychopharmacology. 23: 120-129. PMID 18408526 DOI: 10.1097/Yic.0B013E3282F948F5 |
0.334 |
|
2008 |
Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Current Alzheimer Research. 5: 83-9. PMID 18288936 DOI: 10.2174/156720508783884576 |
0.493 |
|
2008 |
Schneider LS, Qizilbash N, Sano M, Massoud F, Kaye J, Olin JT, Laake K, Øksengaard AR, Oken BS, Yaffe K, Hashimoto K, López-Arrieta J, Breitner JCS, Flicker L, Rockwood K, et al. Treatment of Alzheimer's Disease (With or Without Cerebrovascular Disease) Evidence Based Dementia Practice. 467-588. DOI: 10.1002/9780470752340.ch34 |
0.502 |
|
2007 |
Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 3: 7-17. PMID 19595910 DOI: 10.1016/J.Jalz.2006.10.004 |
0.491 |
|
2007 |
Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, Jarvik L, Manly J, McRae T, Murphy GM, Olin JT, Regier D, Sano M, Mintzer JE. Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. International Psychogeriatrics / Ipa. 19: 539-58. PMID 17451614 DOI: 10.1017/S104161020700511X |
0.377 |
|
2006 |
Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Disease and Associated Disorders. 20: 263-8. PMID 17132971 DOI: 10.1097/01.Wad.0000213859.35355.59 |
0.487 |
|
2006 |
Schmitt FA, van Dyck CH, Wichems CH, Olin JT. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders. 20: 255-62. PMID 17132970 DOI: 10.1097/01.Wad.0000213860.35355.D4 |
0.485 |
|
2006 |
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 704-15. PMID 16861375 DOI: 10.1097/01.JGP.0000224350.82719.83 |
0.354 |
|
2006 |
van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 428-37. PMID 16670247 DOI: 10.1097/01.Jgp.0000203151.17311.38 |
0.391 |
|
2005 |
Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM. [P-186]: Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease Alzheimer's & Dementia. 1: S67-S67. DOI: 10.1016/j.jalz.2005.06.245 |
0.381 |
|
2004 |
Cummings J, Dyck Cv, Schmitt F, Graham SM, Olin JT, Jin J, Tariot PN. P1-315 Functional and behavioral effects of memantine in Alzheimer's disease Neurobiology of Aging. 25: S186. DOI: 10.1016/S0197-4580(04)80628-6 |
0.388 |
|
2004 |
Schmitt FA, Tariot P, Cummings J, Bell J, Jia D, Olin J. P1-002 Robust response to memantine treatment when functional and behavioral efficacies are combined with cognition Neurobiology of Aging. 25: S93. DOI: 10.1016/S0197-4580(04)80316-6 |
0.308 |
|
2003 |
Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Jeste DV, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, et al. Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. Expert Review of Neurotherapeutics. 3: 99-106. PMID 19810852 DOI: 10.1586/14737175.3.1.99 |
0.545 |
|
2003 |
Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophrenia Bulletin. 29: 57-72. PMID 12908661 DOI: 10.1093/Oxfordjournals.Schbul.A006991 |
0.587 |
|
2003 |
Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand OP, Jeste DV, Krishnan KRR, Lyketsos CG, Lyness JM, Rabins PV, et al. Diagnostic criteria for Depression of Alzheimer disease (DAD) Research and Practice in Alzheimer's Disease. 7: 174-179. |
0.493 |
|
2002 |
Krishnan KR, Delong M, Kraemer H, Carney R, Spiegel D, Gordon C, McDonald W, Dew M, Alexopoulos G, Buckwalter K, Cohen PD, Evans D, Kaufmann PG, Olin J, Otey E, et al. Comorbidity of depression with other medical diseases in the elderly. Biological Psychiatry. 52: 559-88. PMID 12361669 DOI: 10.1016/S0006-3223(02)01472-5 |
0.333 |
|
2002 |
Alexopoulos GS, Buckwalter K, Olin J, Martinez R, Wainscott C, Krishnan KR. Comorbidity of late life depression: an opportunity for research on mechanisms and treatment. Biological Psychiatry. 52: 543-58. PMID 12361668 DOI: 10.1016/S0006-3223(02)01468-3 |
0.334 |
|
2002 |
Olin JT, Dagerman KS, Fox LS, Bowers B, Schneider LS. Increasing ethnic minority participation in Alzheimer disease research. Alzheimer Disease and Associated Disorders. 16: S82-5. PMID 12351920 DOI: 10.1097/00002093-200200002-00009 |
0.513 |
|
2002 |
Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biological Psychiatry. 52: 243-52. PMID 12182930 DOI: 10.1016/S0006-3223(02)01348-3 |
0.436 |
|
2002 |
Alexopoulos GS, Borson S, Cuthbert BN, Devanand DP, Mulsant BH, Olin JT, Oslin DW. Assessment of late life depression. Biological Psychiatry. 52: 164-74. PMID 12182923 DOI: 10.1016/S0006-3223(02)01381-1 |
0.364 |
|
2002 |
Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 10: 129-41. PMID 11925274 DOI: 10.1097/00019442-200203000-00004 |
0.57 |
|
2002 |
Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, et al. Provisional diagnostic criteria for depression of Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 10: 125-8. PMID 11925273 DOI: 10.1097/00019442-200203000-00003 |
0.564 |
|
2002 |
Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. The Cochrane Database of Systematic Reviews. CD000359. PMID 11405961 DOI: 10.1002/14651858.Cd000359 |
0.558 |
|
2001 |
Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 9: 400-5. PMID 11739066 DOI: 10.1097/00019442-200111000-00008 |
0.561 |
|
2001 |
Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 9: 346-60. PMID 11739062 DOI: 10.1097/00019442-200111000-00004 |
0.53 |
|
2001 |
Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease American Journal of Geriatric Psychiatry. 9: 400-405. DOI: 10.1097/00019442-200111000-00008 |
0.511 |
|
2000 |
Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. Targeting specific behavioral symptoms in Alzheimer's disease using carbamazepine: Results of a pilot, placebo-controlled, randomized, 6-week trial Neurobiology of Aging. 21: 169. DOI: 10.1016/S0197-4580(00)82098-9 |
0.567 |
|
1999 |
Ippen CG, Olin JT, Schneider LS. Can caregivers independently rate cognitive and behavioral symptoms in Alzheimer's disease patients?: A longitudinal analysis. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 7: 321-30. PMID 10521165 DOI: 10.1097/00019442-199911000-00008 |
0.585 |
|
1999 |
Ippen CG, Olin JT, Schneider LS. Can Caregivers Independently Rate Cognitive and Behavioral Symptoms in Alzheimerʼs Disease Patients? American Journal of Geriatric Psychiatry. 7: 321-330. DOI: 10.1097/00019442-199923740-00008 |
0.522 |
|
1999 |
Olin JT. ENHANCING PARTICIPATION OF HISPANIC PATIENTS IN ALZHEIMER's CLINICAL TRIALS The American Journal of Geriatric Psychiatry. 7: 35. DOI: 10.1097/00019442-199911001-00110 |
0.457 |
|
1999 |
Ippen CG, Olin JT, Schneider LS. Can caregivers independently rate cognitive and behavioral symptoms in Alzheimer's disease patients? A longitudinal analysis American Journal of Geriatric Psychiatry. 7: 321-330. DOI: 10.1097/00019442-199911000-00008 |
0.539 |
|
1999 |
Olin J, Papka M, Jin S, Sano M, Grundman M, Thomas R. Clinical symptoms of dementia with Lewy bodies: Secondary analyses of the Alzheimer's disease cooperative study selegiline and vitamin E clinical trial European Neuropsychopharmacology. 9: 323. DOI: 10.1016/S0924-977X(99)80444-1 |
0.353 |
|
1998 |
Fox LS, Olin JT, Erblich J, Ippen CG, Schneider LS. Severity of cognitive impairment in Alzheimer's disease affects list learning using the California Verbal Learning Test (CVLT). International Journal of Geriatric Psychiatry. 13: 544-9. PMID 9733335 DOI: 10.1002/(Sici)1099-1166(199808)13:8<544::Aid-Gps821>3.0.Co;2-N |
0.536 |
|
1997 |
Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. Journal of the American Geriatrics Society. 45: 923-8. PMID 9256842 DOI: 10.1111/J.1532-5415.1997.Tb02960.X |
0.591 |
|
1997 |
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S22-32. PMID 9236949 DOI: 10.1097/00002093-199700112-00004 |
0.552 |
|
1997 |
Olin JT, Zelinski EM. Age differences in calibration of comprehension Educational Gerontology. 23: 67-77. DOI: 10.1080/0360127970230106 |
0.562 |
|
1997 |
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Alzheimer Disease & Associated Disorders. 11: 425-429. DOI: 10.1007/978-1-4612-4116-4_64 |
0.554 |
|
1996 |
Schneider LS, Olin JT. Clinical global impressions in Alzheimer's clinical trials. International Psychogeriatrics / Ipa. 8: 277-88; discussion 2. PMID 8994897 DOI: 10.1017/S1041610296002645 |
0.591 |
|
1996 |
Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, Reisberg B, Schmitt FA. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. Journal of Geriatric Psychiatry and Neurology. 9: 176-80. PMID 8970010 DOI: 10.1177/089198879600900404 |
0.612 |
|
1995 |
Schneider LS, Olin JT. Efficacy of acute treatment for geriatric depression. International Psychogeriatrics / Ipa. 7: 7-25. PMID 8580394 DOI: 10.1017/S1041610295002328 |
0.514 |
|
1995 |
Olin JT, Schneider LS. Assessing response to tacrine using the factor analytic structure of the Alzheimer's disease assessment scale (Adas)—cognitive subscale International Journal of Geriatric Psychiatry. 10: 753-756. DOI: 10.1002/Gps.930100905 |
0.582 |
|
1994 |
Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Archives of Neurology. 51: 787-98. PMID 8042927 DOI: 10.1001/Archneur.1994.00540200063018 |
0.558 |
|
1993 |
Schneider LS, Olin JT, Pawluczyk S. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. The American Journal of Psychiatry. 150: 321-3. PMID 8422085 |
0.524 |
|
1992 |
Olin JT, Schneider LS, Eaton EM, Zemansky MF, Pollock VE. The Geriatric Depression Scale and the Beck Depression Inventory as Screening Instruments in an Older Adult Outpatient Population Psychological Assessment. 4: 190-192. DOI: 10.1037/1040-3590.4.2.190 |
0.475 |
|
1991 |
Olin JT, Zelinski EM. The 12-Month Reliability of the Mini-Mental State Examination Psychological Assessment. 3: 427-432. DOI: 10.1037/1040-3590.3.3.427 |
0.546 |
|
Show low-probability matches. |